|
Título:
|
Clonidine in patients undergoing noncardiac surgery
|
|
Autores:
|
Devereaux, P.J. ;
Sessler, D.I. ;
Leslie, K. ;
Kurz, A. ;
Mrkobrada, M. ;
Alonso-Coello, P. ;
Villar, J.C. ;
Sigamani, A. ;
Biccard, B.M. ;
Meyhoff, C.S. ;
Parlow, J.L. ;
Guyatt, G. ;
Robinson, A. ;
Garg, A.X. ;
Rodseth, R.N. ;
Botto, F. ;
Lurati Buse, G. ;
Xavier, D. ;
Chan, M.T.V. ;
Tiboni, M. ;
Cook, D. ;
Kumar, P.A. ;
Forget, P. ;
Malaga, G. ;
Fleischmann, E. ;
Amir, M. ;
Eikelboom, J. ;
Mizera, R. ;
Torres, D. ;
Wang, C.Y. ;
VanHelder, T. ;
Paniagua, P. ;
Berwanger, O. ;
Srinathan, S. ;
Graham, M. ;
Pasin, L. ;
Le Manach, Y. ;
Gao, P. ;
Pogue, J. ;
Whitlock, R. ;
Lamy, A. ;
Kearon, C. ;
Chow, C. ;
Pettit, S. ;
Chrolavicius, S. ;
Yusuf, S.
|
|
Tipo de documento:
|
texto impreso
|
|
Editorial:
|
Massachusetts Medical Society, 2020-06-10T18:12:14Z
|
|
Nota general:
|
info:eu-repo/semantics/restrictedAccess
https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
|
|
Idiomas:
|
Inglés
|
|
Palabras clave:
|
Editados por otras instituciones
,
Artículos
,
Artículos en revistas indizadas
|
|
Resumen:
|
BACKGROUND: Marked activation of the sympathetic nervous system occurs during and after non-cardiac surgery. Low-dose clonidine, which blunts central sympathetic outflow, may prevent perioperative myocardial infarction and death without inducing hemodynamic instability. METHODS: We performed a blinded, randomized trial with a 2-by-2 factorial design to allow separate evaluation of low-dose clonidine versus placebo and low-dose aspirin versus placebo in patients with, or at risk for, atherosclerotic disease who were undergoing noncardiac surgery. A total of 10,010 patients at 135 centers in 23 countries were enrolled. For the comparison of clonidine with placebo, patients were randomly assigned to receive clonidine (0.2 mg per day) or placebo just before surgery, with the study drug continued until 72 hours after surgery. The primary outcome was a composite of death or nonfatal myocardial infarction at 30 days. RESULTS: Clonidine, as compared with placebo, did not reduce the number of primary-outcome events (367 and 339, respectively; hazard ratio with clonidine, 1.08; 95% confidence interval [CI], 0.93 to 1.26; P=0.29). Myocardial infarction occurred in 329 patients (6.6%) assigned to clonidine and in 295 patients (5.9%) assigned to placebo (hazard ratio, 1.11; 95% CI, 0.95 to 1.30; P=0.18). Significantly more patients in the clonidine group than in the placebo group had clinically important hypotension (2385 patients [47.6%] vs. 1854 patients [37.1%]; hazard ratio 1.32; 95% CI, 1.24 to 1.40; P
|
|
En línea:
|
http://doi.org/10.1056/NEJMoa1401106
|
